AMAG Pharmaceuticals, Inc. (AMAG)
IDA-301 Data Conference Call
July 18, 2012 08:00 am ET
Bill Heiden – President & Chief Executive Officer
Lee Allen, MD – Chief Medical Officer
Frank Thomas – Chief Operating Officer
Amy Sullivan – Vice President, Investor Relations and Corporate Communications
Mike – JP Morgan
Sarah – Morgan Stanley
Eun Yang – Jefferies & Company
Carol Werther – Summer Street Research Partners
Matt McKinsey – Robert W. Baird & Co.
Good morning, my name is Justine and I will be your conference operator today. At this time I would like to welcome everyone to the AMAG Pharmaceuticals’ Conference Call. (Operator instructions.) Thank you. Vice President of Investor Relations Amy Sullivan, you may begin your conference.
Thank you, Justine. Good morning, and welcome to the AMAG Pharmaceuticals’ Conference Call to discuss preliminary data from the second of two Phase III studies evaluating Feraheme for the treatment of iron deficiency anemia in a broad range of patients.
We issued a press release earlier this morning that contains the top line data from the study. We have focused the data relating to the key points to allow us to preserve our options to present the full dataset at appropriate medical conferences and journals in the future. If you haven’t received a copy of the release you can get it from the investors section of our website at
Before proceeding with this call, please be reminded that any statements we make during the course of this conference call that are other than historical facts are forward-looking statements made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. We want to emphasize that these forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Please refer to our recent filings with the SEC for a full review of the risks and uncertainties associated with our business.